Clinical Trials Browser

INDUSTRY × Has results × duvelisib × Clear all

NCT03372057 2025-03-07

PRIMO

Phase 2 Completed

156 enrolled 21 charts

Lymphoma, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

13 enrolled 10 charts 1 FDA

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02391545 2023-09-28

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Phase 1/2 Terminated

55 enrolled 13 charts

Lymphoma, Follicular

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Phase 3 Completed

319 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02049515 2023-09-21

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Phase 3 Completed

99 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02711852 2023-09-11

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Phase 2 Completed

19 enrolled 11 charts

Other hematologic neoplasm

Hematologic Neoplasms